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Abstract: Background
Comorbidities defined by the Charlson comorbidity index (CCI) and body mass index
(BMI) are significantly associated with outcome in patients who receive continuous
treatment with tyrosine kinase inhibitors.
Methods
We evaluated the impact of CCI and BMI on responses, drug-related toxicities and
outcome in a cohort of 402 patients with myelofibrosis (MF) treated with ruxolitinib in 23
European Hematology Centers.
Results
Comorbidities were evaluable in all 402 patients. A higher (>3) CCI did not correlate
with a lower spleen reduction at any time (p=0.68) or symptoms’ response (p=0.11),
but influenced the onset of anemia (all grades) any time and during the first 3 months
of treatment and later (p=0.04 and p=0.03, respectively). BMI was evaluable in 380
patients and did not correlate with differences in spleen and symptoms response
(p=0.57 and p=0.49, respectively). A higher CCI and a lower BMI correlated also with a
reduced overall survival (p<0.001 and p=0.02, respectively). The achievement of a
spleen response at 6 months could counterbalance the negative impact of
comorbidities, while patients who were underweight when starting ruxolitinib and did
not achieve a spleen response at 6 months were projected to the worse outcome.
Conclusions
In MF patients treated with ruxolitinib, BMI and comorbidities did not influence the
achievement of spleen/symptom responses, but they contributed to the early
identification of patients who deserve a strict monitoring during treatment.
Response to Reviewers: Reviewer #1
Interesting analyses on outcome of MF patients also correlating comorbidities and BMI.
Some points to discuss:
- It should be discussed if patients with MF per se should be counted in the CCI with 2
points (Definition leukemia: Leukemia - malignancy due to abnormal function of the
bone marrow and the other blood forming organs with an increased number of
immature and/or abnormal leucocytes) at least for patients with advanced phases.
     We agree with the Reviewer that all patients carry the same hematological
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malignancy (MF); however, if we add 2 points for each patient (applying the term
“leukemia” to all MF patients), the results of the present analysis would not change.
Therefore, we have assigned 2 points only in case of additional malignancy prior to
ruxolitinib start. This has been specified in the Material and Methods Section.
- For the BMI categories it would be interesting how the values were set. Was there
any approach to have the analyses done by minimal p-value approach?
     Minimal p-value approach was not used for the division in categories according to
BMI. We stratified patients into 3 categories according to BMI, with the aim of
comparing underweight, normal-weight and overweight patients. The first cut-off was
however set at 21.9 in order to include the first quartile (n.96) of patients, to avoid
having small numbers (only 3.2% pts had a BMI <18.5) thereby preventing substantial
losses in statistical power, while the second cut-off was set at 25, in order to isolate the
overweight group of patients, in compliance with the WHO stratification criteria.
This was specified in the Result Section (Impact of comorbidities and BMI on response
to ruxolitinib).
- How many patients were transplanted and were they censored for survival analyses?
     Overall, 17 (4.2%). patients were submitted to allogeneic stem cell transplant after
ruxolitinib failure. These patients were censored at the time of transplant for survival
analysis.
This has been specified in the Result Section (Impact of comorbidities and BMI on
outcome).
- The figures are difficult to read in the current outline (the differences in Grey are
margial).
      Ok, figures have been edited in order to improve their readability also in black and
white.
 
Reviewer #2
     This multicenter study analyzed the impact of comorbidities (defined according to
the Charlson comorbidity index , CCI) and body mass index (BMI) on responses, drug-
related toxicities and outcome in a cohort of 402 patients with myelofibrosis (MF)
treated with ruxolitinib. Main results showed that neither comorbidities nor BMI
influence the probability of achieving a response on spleen or systemic symptoms
during ruxolitinib treatment. Severe anemia, thrombocytopenia and the incidence of
infections were not influenced by CCI and BMI. As expected, a higher CCI and a lower
BMI correlated with a reduced overall survival. The Authors concluded that
comorbidities and BMI do not seem to be a contraindication for ruxolitinib therapy in
MF patients.
Major scientific issues
1.The issue of anemia should be better addressed. Anemia was already present at
ruxolinib start (tab. 1) and "patients with an increased burden of comorbidities
presented more frequently anemia at baseline" (Discussion, para 2, line 7). Therefore,
the statement that "comorbidities influenced the onset of ruxolitinib-related anemia (all
grades) " (Abstract, results, lines 2-3 and page 4, toxicity, para 2, first line) is
confusing, since anemia was already present and was not ruxolitinib-related.
Accordingly, the hemoglobin level at baseline could be sufficient for 'the early
identification of patients who deserve a strict monitoring during treatment' without using
the CCI; thus, the last sentence of the Abstract is futile.
       In the first version of the paper, drug-induced anaemia was defined according to
National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) v
4.0
(https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-
14_QuickReference_5x7.pdf). Patients that were transfusion-dependent before the
start of ruxolitinib therapy were not evaluable for drug-related anaemia. However,
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patients with baseline MF-related anemia (haemoglobin levels below 12 g/dl in
absence of transfusion requirement) were included in the analysis.
We agree with the Reviewer that this analysis may be confusing.
Therefore, firstly, we have repeated the analysis taking into account only drug-induced
anemia, defined as increasing in anemia grade with respect to baseline levels. This
analysis failed to show any impact of BMI and CCI on drug-induced anemia. These
results are reported in the Results section and in Table 2, which has been revised.
Secondly, we have analysed the incidence of anemia only in the 132 patients that
started ruxolitinib without anemia (i.e: with a haemoglobin level ≥ 12 g/dl in absence of
transfusion requirement). Here, we demonstrated that patients with CCI≥3 had a higher
incidence of ruxolitinib-induced grade-≥2 anemia at 3 months and at any time during
therapy. Therefore, our statement that comorbidities influenced the onset of ruxolitinib-
related anemia is valid for ruxolitinib-induced grade-≥2 anemia, These results are now
reported in the Results section and in a new Table 3.
2. The statistical analysis reported in fig. 2a and b is unclear. At which comparisons the
p values are applied ?
     The p-values in Figures 2a and 2b are results of Log-rank tests and represent the
overall difference between the Kaplan-Meier curves.
We have expanded the analysis with pair-wise Log-rank tests between the curves, and
the p-values of the single log-rank pairwise survival comparisons are reported in the
description of Figure 2 and confirm that the categories that significantly differ from the
others (and that majorly impact on the overall difference between the categories) are
represented, in Figure 2a, by the group of patients with a spleen response and with
lower CCI, that have a significantly improved Overall Survival compared to the others,
and, in Figure 2b, by the patients with no spleen response and a lower BMI, that have
a significantly worse Overall Survival compared to the others.
3. Some conclusions are not supported by data, such as "The cut-off of CCI (< 3) could
be of help to identify patients who may deserve a treatment with ruxolitinib…
(Discussion, para 2, lines 5-6)". Actually, the results did not show differences in the
response to ruxolitinib according to CCI.
       Ok. This sentence actually referred to the result that the patients with both spleen
response and CCI<3 are projected to longer survival (Figure 2a) and may therefore
represent the best target population for ruxolitinib therapy.
The sentence has been rephrased in the text and is now clearer.
Other points
1. Several repetitions should be avoided. For example, the information that 'BMI was
evaluated in 380 patients' is given four times in the paper.
    Ok, repetitions have been deleted.
2. Ref. 25 should be corrected.
       Ok, ref 25 has been edited.
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Table 1. Patients’ characteristics at ruxolitinib start. Post-PV MF: Post-Polycythemia vera Myelofibrosis; Post-ET MF: 
Post-Essential Thrombocythemia Myelofibrosis. DIPSS: Dynamic International Prognostic Score System.  
 
Characteristics Patients (n. 402) 
Male sex, n. (%) 233 (58.0%) 
Primary MF, n. (%) 212 (52.7%) 
Post-PV MF, n. (%) 117 (29.1%) 
Post-ET MF, n. (%) 73 (18.2%) 
DIPSS risk score, on 363 evaluable patients, n. (%) 
Intermediate-1 
Intermediate-2 
High 
 
156 (43.0%) 
183 (50.4%) 
24 (6.6%) 
Median hemoglobin, g/dl (range) 10.7 (4.7-16.7) 
Transfusion dependence, n. (%) 102 (25.4%) 
Median platelet count, x10
9
/l (range) 248.5 (32.9-1632) 
Palpable spleen, n. (%) 386 (96.0%) 
Spleen ≥10 cm, n. (%) 252 (62.7%) 
Median Body Mass Index (BMI), n. (% on 380 evaluable patients) 23.9 (15.5-33.3) 
BMI <21.9 (first quartile) 96 (25.3%) 
BMI 21.9-24.9 (normal weight) 141 (37.1%) 
BMI ≥25 (overweight) 143 (37.6%) 
Unfavorable karyotype, n. (% on 213 evaluable patients) 16 (7.5%) 
JAK2
V617F 
, n. (% on 321 evaluable patients) 282 (87.9%) 
CALR, n. (% on 321 evaluable patients) 26 (8.1%) 
MPL, n. (% on 321 evaluable patients) 1 (0.3%) 
Triple negative, n. (% on 321 evaluable patients) 12 (3.7%) 
Median time from MF diagnosis to ruxolitinib start, months 16.1 (0-290.5) 
Ruxolitinib starting dose, n. (%) 
5 mg BID 
10 mg BID 
15 mg BID 
20 mg BID 
 
55 (13.7%) 
38 (9.5%) 
103 (25.6%) 
206 (51.2%) 
Median follow-up from ruxolitinib start, months (range) 23.1 (1.1-68.0) 
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Abstract 
 
Background. Comorbidities defined by the Charlson comorbidity index (CCI) and body 
mass index (BMI) are significantly associated with outcome in patients who receive continuous 
treatment with tyrosine kinase inhibitors.  
Methods. We evaluated the impact of CCI and BMI on responses, drug-related toxicities 
and outcome in a cohort of 402 patients with myelofibrosis (MF) treated with ruxolitinib in 23 
European Hematology Centers.  
Results. Comorbidities were evaluable in all 402 patients. A higher (≥3) CCI did not 
correlate with a lower spleen reduction at any time (p=0.68) or symptoms’ response (p=0.11), but 
influenced the onset of anemia during the first 3 months of treatment and later (p=0.02 and p=0.03, 
respectively) in patients without anemia baseline. BMI was evaluable in 380 patients and did not 
correlate with differences in spleen and symptoms response (p=0.57 and p=0.49, respectively). A 
higher CCI and a lower BMI correlated also with a reduced overall survival (p<0.001 and p=0.02, 
respectively). The achievement of a spleen response at 6 months could counterbalance the negative 
impact of comorbidities, while patients who were underweight when starting ruxolitinib and did not 
achieve a spleen response at 6 months were projected to the worse outcome. 
Conclusions. In MF patients treated with ruxolitinib, BMI and comorbidities did not 
influence the achievement of spleen/symptom responses, but they contributed to the early 
identification of patients who deserve a strict monitoring during treatment. 
 
 
Introduction 
 
In the last few years, several reports have demonstrated the impact of comorbidities on 
survival in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). 
Indeed, the German group has shown in a large CML series that a higher Charlson comorbidity 
index (CCI) at baseline significantly correlated with reduced survival regardless of the response 
achieved during imatinib therapy [1]. In addition, comorbidities predicted worse prognosis in 
patients with primary myelofibrosis [2]. Together with comorbidities, also body mass index may be 
relevant in prognosis of patients with cancer [3]. According to WHO criteria, people may be 
stratified into four categories: underweight (BMI <18.5), normal weight (18.5-25), overweight (25-
30) and obese (≥30) [4]. Increased BMI was associated with delayed cytogenetic and major 
molecular responses to imatinib in CML patients [5].  
Ruxolitinib is the first JAK1/JAK2 inhibitor approved for the treatment of splenomegaly and 
symptoms associated with myelofibrosis (MF). The prospective COMFORT 1 and COMFORT 2 
studies randomized MF patients to receive either ruxolitinib or placebo and best available therapies, 
respectively, demonstrating the superiority of ruxolitinib in terms of reduction of splenomegaly, 
amelioration of symptoms and improvement of quality of life [6, 7]. A longer follow-up of the 
COMFORT studies also documented a survival advantage of patients treated with ruxolitinib 
compared to placebo and best available treatment [8, 9]. The impact of comorbidities has not been 
detailed systematically in the COMFORT studies or the JUMP trial [10] and only 13% of patients 
assigned to ruxolitinib showed a performance score ECOG >2 in the COMFORT-II trial [8]. 
Therefore, a clear benefit of ruxolitinib for patients with impaired clinical conditions has never been 
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 3 
demonstrated and the European LeukemiaNet/SIE panel has suggested to avoid the drug in frail 
patients [11]. 
Here, we retrospectively assessed the impact of comorbidities and BMI on clinical 
responses, overall survival and maintenance of ruxolitinib dose in a large cohort of MF patients. 
 
Methods 
 
An electronic database was established to collect clinical, molecular and laboratory data on 
MF patients treated with ruxolitinib in 23 European Hematology Centers as previously described 
[12]. Between June 2011 and November 2016, data on 462 consecutive MF patients were 
retrospectively collected. Data cut-off was January 2018. Two-hundred and thirty-four patients 
were enrolled in the JUMP trial (ClinicalTrials.gov Identifiers: NCT01493414) and 168 patients 
received ruxolitinib as compassionate or commercial use/off-study according to the standard 
clinical practice. 
A diagnosis of primary myelofibrosis (PMF) and post-essential 
thrombocythemia/polycythemia vera myelofibrosis (post-ET/post-PV MF) was made according to 
the WHO 2008 [13] or the International Working Group on Myelofibrosis Research and Treatment 
(IWG-MRT) criteria [14]. Bone marrow fibrosis was graded according to the European Consensus 
Grading System [15]. Evolution into blast phase was based on the WHO classification [16]. 
Molecular tests for detection of JAK2, MPL and CALR mutations and cytogenetic analysis were 
carried out as described elsewhere [17]. Ruxolitinib was administrated according to the prescribing 
information. Spleen and symptoms’ responses have been defined according to the International 
Working Group on Myelofibrosis Research and Treatment / European Leukemia Net (IWG-
MRT/ELN) criteria [18]. Symptoms’ response was assessed by changes in the Myeloproliferative 
Neoplasm Symptom Assessment Form total symptoms score (TSS) [19].  
Anemia and thrombocytopenia were graded according to National Cancer Institute Common 
Toxicity Criteria for Adverse Events (NCI-CTCAE) v 4.0 (https://www.eortc.be/services/doc/ctc/ 
CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf). Drug-induced anemia and thrombocytopenia 
were defined as increasing in anemia/thrombocytopenia grade with respect to baseline levels. 
Patients that were transfusion-dependent before the start of ruxolitinib therapy were not evaluable 
for subsequent anemia. 
BMI was calculated at the time of start of ruxolitinib treatment. BMI was defined as the 
individual’s body weight in Kg divided by the square of his/her height, which produces a unit of 
measure of Kg/m2.  
Comorbidities were recorded at the time of the start of ruxolitinib and classified according to 
the CCI [20]. Comorbidities were evaluated at baseline, before ruxolitinib treatment, by the medical 
staff. All information about concomitant diseases and drug usage were recorded in each case history 
and thereafter used for this retrospective evaluation. As reported, CCI is a list of 19 comorbid 
conditions: each condition has a weight assigned from 1 to 6, which is derived from the relative risk 
estimates of a proportional hazard regression model using clinical data. For the condition 
“leukemia-malignancy”, 2 points were assigned only in case of occurrence of an additional malignancy 
to MF prior to ruxolitinib start. 
The study was approved by the Institutional Review Board of each Institution and was 
conducted according to the Helsinki declaration. Clinical and laboratory parameters were evaluated 
both at diagnosis and at the start of ruxolitinib. 
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Statistical analysis 
Categorical variables have been summarized by their median and range or mean and 
standard deviation, according to the statistical analysis performed, and categorical variables by 
count and relative frequency (%) of each category. Comparisons of continuous variables between 
groups of patients were carried out using the Wilcoxon-Mann-Whitney rank-sum test or the 
Student’s t-test, when compared between two groups, or the ANOVA or Kruskal-Wallis tests, when 
compared between 3 groups, and the association between categorical variables (2-way tables) was 
tested by the Fisher exact test or χ2, as appropriate. Overall Survivals (OS) were performed using 
Kaplan-Meier analysis, from the start of ruxolitinib to death or last contact, and compared by the 
log-rank test, also used for pairwise comparisons when considering multiple categories. 
Progression-free survival (PFS) took into account death from any cause and progression to blast 
phase. When calculating OS and PFS from the start of ruxolitinib, the survival analysis was 
adjusted for left truncation (“delayed entry”). When adjusting for the Dynamic International 
Prognostic Score System (DIPSS) category at treatment, OS and PFS were calculated using the Cox 
proportional hazards multivariate regression model. The cumulative incidence of infections was 
calculated considering death as competing risk, according to the model of Fine and Gray. All 
reported p values are two-sided, and p values <0.05 were considered statistically significant. All 
statistical analyses were performed with STATA15. 
 
Results 
Study cohort 
Between June 2011 and April 2016, 462 MF patients were treated with ruxolitinib in the 
participating Centers. Of the whole cohort, a total of 402 patients were evaluable for CCI and were 
included in this study. Three hundred and eighty patients (94.5%) had also data on BMI at the start 
of treatment. 
At ruxolitinib start, the median age was 64 years (range 39-89) with a male prevalence 
(52.4%). Diagnosis was PMF in 212 patients (52.7%), post-PV MF in 117 patients (29.1%) or post-
ET MF in 18.2% of cases. The IPSS at ruxolitinib start was intermediate-1 in 15.7% of cases, 
intermediate-2 in 46.5% or high in 37.8%. The median follow-up from MF diagnosis to the last 
contact was 3.8 years (range 0.2-34.8) and the median exposure to ruxolitinib exposure 23.1 months 
(range, 1.1-68) (Table 1). 
Among the 402 evaluable patients, 198 (49.2%) had no comorbidities, 128 (31.8%) had a 
CCI 1-2 and 76 (40.7%) a CCI ≥3, with a median of 1 comorbidity per patient (range 0-8). The 
most common comorbidities were peripheral vascular disease (14%), previous solid tumor (13.5%), 
diabetes (10%) and liver disease (9.6%). Compared to patients with CCI=0, patients with CCI 1-2 
and ≥3 were more frequently in the intermediate-2 DIPPS category (p=0.03), with a hemoglobin 
level <10 gr/dl (33.8% in CCI=0, 43.7% in CCI=1-2 and 56.6% in CCI≥3, p=0.005) and transfusion 
dependence (20% vs 28.1% and 34.2%, p=0.04).  
Overall, 12 patients (3.2%) had a BMI <18.5, 225 (59.2%) were normal weighted, 123 
(32.4%) a BMI between 25 and 30 while 20 patients (5.2%) were obese. Median BMI was 23.9 
(range: 15.5-33.3). Overweight patients (BMI ≥25) were more frequently males (p=0.001), 
belonged more frequently to the intermediate-1 DIPSS category, and had less anemia: a hemoglobin 
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 5 
value <10 gr/dl at presentation was found in 45.0% of patients with a BMI <25 and 33.8% with a 
BMI ≥25 (p=0.03). The burden of symptoms, in terms of presence of constitutional symptoms and 
average 10-item TSS was not significantly influenced by CCI and BMI. 
Impact of comorbidities and BMI on response to ruxolitinib 
Overall, 354 patients were evaluable for spleen response and 379 for symptoms response 
according to the IWG-MRT criteria. A total of 138 (39.0%) and 309 (81.5%) patients achieved a 
spleen or a symptom response at any time during therapy, respectively. More specifically, at 3 and 6 
months 100 (28.2%) and 122 (37.9%) out of 354 and 322 evaluable patients were in spleen 
response, while 277 (73%) and 263 (82.1%) out of 379 and 320 evaluable patients were in 
symptoms response, respectively. 
By stratifying patients into 3 categories with different CCI (CCI=0, CCI 1-2 and CCI≥3), a 
higher CCI did not correlate with a lower spleen response at any time (achieved by 37.6%, 38.5% 
and 43.7% of patients with CCI=0, 1-2 and ≥3, respectively, p=0.68), or symptoms response at any 
time (achieved by 77.3%, 85.9% and 84.9% in patients with CCI=0, 1-2 and ≥3, respectively, 
p=0.11). The rates of spleen and symptoms responses were also comparable at 3 and 6 months 
across the three CCI groups. 
Patients were also subdivided into three categories according to a BMI below the first 
quartile (<21.9, n.96), a BMI between 21.9 and 24.9 (normal weight, n. 142) and BMI ≥25 
(overweight, n. 142). BMI categories were not significantly associated with differences in spleen 
response (achieved by 40.7%, 35.2% and 41.3% of patients with a BMI <21.9, 21-24.9 and ≥25, 
respectively, p=0.57), or symptom response (achieved by 79.3%, 79.7% and 84.6% of patients, 
respectively, p=0.49) at any time. Also, the rates of spleen and symptoms responses were 
comparable across the three groups of patients both at 3 (p=0.85 and p=0.32) and 6 months (p=0.73 
and p=0.63). 
Average starting and overall ruxolitinib doses were comparable across both CCI (p= 0.78) 
and BMI (p = 0.37) groups. 
 
Impact of comorbidities and BMI on toxicity to ruxolitinib 
Overall, 229 (75.6%) of 303 evaluable patients, who were not transfusion-dependent at the 
start of ruxolitinib, experienced an increase in anemia grade; comorbidities and BMI did not 
influence the increase of ruxolitinib-related anemia grade over time (Table 2). However, the 
incidence of ruxolitinib-induced grade ≥2 anemia in the 132 patients that started ruxolitinib without 
anemia (i.e: with a haemoglobin level ≥ 12 g/dl in absence of transfusion requirement) was 
significantly higher in patients with CCI≥3 (Table 3).  
Thrombocytopenia of any grade at any time was observed in 204 of the 394 evaluable 
patients (grade 3-4 in 10.8%) and was never associated with CCI and BMI (Tables 2 and 3). 
 
 
Infections grade ≥2 occurred in 120 (29.9%) patients, after a median time form ruxolitinib 
start of 5.9 months (range: 1-60.9). More specifically, infections were: pneumonia in 25.8% of 
cases (grade 2 in 11 patients, grade 3 in 14 and grade 4-5 in 6), bronchitis in 15% of cases (grade 2 
in 16 patient and grade 3 in two), gastrointestinal infections in 8.3% of cases (grade 2 in 4 patients, 
grade 3 in 5 and grade 4 in 1), urinary tract infections in 8.3% of cases (grade 2 in 9 patients and 
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grade 3 in 1), Herpesvirus Infections in 10% of cases (grade-2 Herpes Simplex infections in 6 
patients and grade-2 and grade-3 Herpes zoster infections in 5 and 1 patient, respectively), 
cutaneous infections in 5.8% of cases (grade-2 in 6 patients and grade-3 in 1), upper airways 
infections in 7.7% of cases (grade-2 in 8 patients and grade-3 in 1), fever in 15% of cases (grade-2 
in 13 patients and grade 3-4 in 5), sepsis in 1.7% of cases (one grade-3 and grade-4 in 1). In 
addition, grade-2 tuberculosis, grade-2 eye infection and grade-2 renal infection were recorded in 1 
patient each. After adjustment for risk of death, the cumulative incidence of infections during 
treatment was not influenced by CCI and BMI stratification (p=0.27 and p=0.95, respectively). 
Impact of comorbidities and BMI on outcome 
Overall, 17 (4.2%). patients were submitted to allogeneic stem cell transplant after 
ruxolitinib failure. These patients were censored at the time of transplant for survival analysis. 
Accounting for left-truncation, overall and progression-free survival differed significantly 
between the different CCI groups (p=0.01 and 0.04, respectively). CCI maintained its prognostic 
value even when adjusted for DIPSS (p<0.001 and 0.001, respectively) (Figure 1a and 1b). As in 
the CCI stratification, also the BMI correlated with DIPSS-adjusted OS (p=0.003) and PFS 
(p=0.003) (Figure 1c and 1d) after left truncation. 
A landmark Kaplan-Meier survival analysis, from 6 months from ruxolitinib start onwards, 
was performed to compare patients according to response to ruxolitinib at 6 months and CCI. Log-
rank tests showed that patients with an IWG-MRT-defined spleen response and a CCI <3 had the 
best OS compared to all the other categories (Figure 2a). Notably, in patients with a comparable 
CCI below 3, the achievement of a spleen response at 6 months significantly improved OS. Log-
rank tests also showed that patients who did not obtain a response and with a BMI <21.9 had the 
worse outcome (Figure 2b). Here, achieving a spleen response could significantly improve the 
outcome of patients starting treatment while underweight. 
Discussion 
Comorbidities influence the prognosis of patients affected by cancers and impact on 
treatment decisions [2, 21-23]. While an accurate evaluation of comorbidities and nutritional status 
is now part of the routine baseline assessment of CML patients, these parameters have never been 
investigated in depth in patients with MF treated with ruxolitinib.  
Our analysis in a large series of MF patients homogeneously treated with ruxolitinib in the 
clinical practice showed that baseline comorbidities, such as in other diseases, have a role in 
predicting survival, but do not influence the probability of achieving a spleen response or the 
control of inflammation-related symptoms. Also, patients with a lower burden of comorbidities at 
baseline who achieve a spleen response seem to have a better prognosis compared to non-
responders with a similar CCI. This cut-off of CCI (< 3) could be of help to identify patients who 
may deserve a treatment with ruxolitinib, considering that a spleen response with a limited burden 
of comorbid conditions may result in the best outcome. We found that patients with an increased 
burden of comorbidities present more frequently anemia at baseline and during therapy: physicians 
must be aware that a strict weekly monitoring should be carried out to check the onset of 
transfusion-dependence if CCI is higher than 3 at baseline. 
Unlike in CML, BMI did not impact significantly on the response rates or on the onset of 
toxicities in MF patients treated with ruxolitinib. On the contrary, the drug is likely to ameliorate 
MF-related cachexia resulting in improved survival through the improvement of cytokine levels. 
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The achievement of a spleen response in patients with initial disease-related cachexia correlated 
with an improvement of OS compared to patients with a similar BMI but who did not achieve such 
a response. Therefore, MF-related cachexia should not prevent per se the choice of starting 
treatment with ruxolitinib. 
Our group has recently proposed a comprehensive assessment for frail patients with 
Philadelphia-positive and –negative chronic myeloproliferative neoplasms who need to be treated 
with TKIs: BMI evaluation was included together with performance status, instrumental activities 
of daily living, CCI and short physical performance battery (SPPB) [24]. More recently, an 
innovative “cachexia index” was proposed in order to provide a more objective quantification of 
constitutional symptoms in PMF [25]. This score takes two widely available laboratory tests into 
account: serum albumin and cholesterol levels, which were found to correlate with survival 
regardless of IPSS/DIPSS category. Overall, these parameters may reflect the 
hypercatabolic/cachectic state of the disease and confirm the role of the nutritional status on 
outcome  [25]. 
In conclusion, comorbidities and BMI do not seem to be a contraindication for ruxolitinib 
therapy in MF patients, but may contribute to better define the profile of patients who deserve a 
strict monitoring during treatment. 
 
 
 
 
Ethical standards statement 
All procedures followed were in accordance with the ethical standards of the responsible committee 
on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as 
revised in 2008 (5). 
 
 
Statement of informed consent 
Informed consent was obtained from all patients for being included in the study. 
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please find enclosed our revised paper “IMPACT OF COMORBIDITIES AND BODY MASS 
INDEX IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB” 
(AOHE-D-18-00894) for Annals of Hematology journal, which has been modified according to 
referees’ comments.  
We detail below all changes made and look forward to your reply at your earliest convenience.  
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Reviewers' Comments;Breccia et al_AOHE_RESPONSE TO
Reviewer #1 
 
Interesting analyses on outcome of MF patients also correlating comorbidities and BMI. Some 
points to discuss: 
 
- It should be discussed if patients with MF per se should be counted in the CCI with 2 points 
(Definition leukemia: Leukemia - malignancy due to abnormal function of the bone marrow 
and the other blood forming organs with an increased number of immature and/or abnormal 
leucocytes) at least for patients with advanced phases. 
We agree with the Reviewer that all patients carry the same hematological malignancy (MF); 
however, if we add 2 points for each patient (applying the term “leukemia” to all MF patients), 
the results of the present analysis would not change. Therefore, we have assigned 2 points only in 
case of additional malignancy prior to ruxolitinib start. This has been specified in the Material 
and Methods Section. 
 
 
- For the BMI categories it would be interesting how the values were set. Was there any 
approach to have the analyses done by minimal p-value approach? 
Minimal p-value approach was not used for the division in categories according to BMI. We 
stratified patients into 3 categories according to BMI, with the aim of comparing underweight, 
normal-weight and overweight patients. The first cut-off was however set at 21.9 in order to 
include the first quartile (n.96) of patients, to avoid having small numbers (only 3.2% pts had a 
BMI <18.5) thereby preventing substantial losses in statistical power, while the second cut-off was 
set at 25, in order to isolate the overweight group of patients, in compliance with the WHO 
stratification criteria. 
This was specified in the Result Section (Impact of comorbidities and BMI on response to 
ruxolitinib). 
 
 
- How many patients were transplanted and were they censored for survival analyses? 
Overall, 17 (4.2%). patients were submitted to allogeneic stem cell transplant after ruxolitinib 
failure. These patients were censored at the time of transplant for survival analysis.  
This has been specified in the Result Section (Impact of comorbidities and BMI on outcome). 
 
 
- The figures are difficult to read in the current outline (the differences in Grey are margial). 
Ok, figures have been edited in order to improve their readability also in black and white. 
  
Reviewer #2 
This multicenter study analyzed the impact of comorbidities (defined according to the Charlson 
comorbidity index , CCI) and body mass index (BMI) on responses, drug-related toxicities and 
outcome in a cohort of 402 patients with myelofibrosis (MF) treated with ruxolitinib. Main 
results showed that neither comorbidities nor BMI influence the probability of achieving a 
response on spleen or systemic symptoms during ruxolitinib treatment. Severe anemia, 
thrombocytopenia and the incidence of infections were not influenced by CCI and BMI. As 
expected, a higher CCI and a lower BMI correlated with a reduced overall survival. The Authors 
concluded that comorbidities and BMI do not seem to be a contraindication for ruxolitinib 
therapy in MF patients. 
Major scientific issues 
 
1.The issue of anemia should be better addressed. Anemia was already present at ruxolinib 
start (tab. 1) and "patients with an increased burden of comorbidities presented more 
frequently anemia at baseline" (Discussion, para 2, line 7). Therefore, the statement that 
"comorbidities influenced the onset of ruxolitinib-related anemia (all grades) " (Abstract, 
results, lines 2-3 and page 4, toxicity, para 2, first line) is confusing, since anemia was already 
present and was not ruxolitinib-related. Accordingly, the hemoglobin level at baseline could be 
sufficient for 'the early identification of patients who deserve a strict monitoring during 
treatment' without using the CCI; thus, the last sentence of the Abstract is futile. 
 
In the first version of the paper, drug-induced anaemia was defined according to National Cancer 
Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) v 4.0   
(https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf). 
Patients that were transfusion-dependent before the start of ruxolitinib therapy were not 
evaluable for drug-related anaemia. However, patients with baseline MF-related anemia 
(haemoglobin levels below 12 g/dl in absence of transfusion requirement) were included in the 
analysis.  
We agree with the Reviewer that this analysis may be confusing.  
Therefore, firstly, we have repeated the analysis taking into account only drug-induced anemia, 
defined as increasing in anemia grade with respect to baseline levels. This analysis failed to show 
any impact of BMI and CCI on drug-induced anemia. These results are reported in the Results 
section and in Table 2, which has been revised. 
Secondly, we have analysed the incidence of anemia only in the 132 patients that started 
ruxolitinib without anemia (i.e: with a haemoglobin level ≥ 12 g/dl in absence of transfusion 
requirement). Here, we demonstrated that patients with CCI≥3 had a higher incidence of 
ruxolitinib-induced grade-≥2 anemia at 3 months and at any time during therapy. Therefore, our 
statement that comorbidities influenced the onset of ruxolitinib-related anemia is valid for 
ruxolitinib-induced grade-≥2 anemia, These results are now reported in the Results section and 
in a new Table 3. 
 
 
2. The statistical analysis reported in fig. 2a and b is unclear. At which comparisons the p values 
are applied ? 
The p-values in Figures 2a and 2b are results of Log-rank tests and represent the overall 
difference between the Kaplan-Meier curves.  
We have expanded the analysis with pair-wise Log-rank tests between the curves, and the p-
values of the single log-rank pairwise survival comparisons are reported in the description of 
Figure 2 and confirm that the categories that significantly differ from the others (and that 
majorly impact on the overall difference between the categories) are represented, in Figure 2a, by 
the group of patients with a spleen response and with lower CCI, that have a significantly 
improved Overall Survival compared to the others, and, in Figure 2b, by the patients with no 
spleen response and a lower BMI, that have a significantly worse Overall Survival compared to 
the others.  
 
 
3. Some conclusions are not supported by data, such as "The cut-off of CCI (< 3) could be of 
help to identify patients who may deserve a treatment with ruxolitinib… (Discussion, para 2, 
lines 5-6)". Actually, the results did not show differences in the response to ruxolitinib 
according to CCI. 
Ok. This sentence actually referred to the result that the patients with both spleen response and 
CCI<3 are projected to longer survival (Figure 2a) and may therefore represent the best target 
population for ruxolitinib therapy.  
The sentence has been rephrased in the text and is now clearer. 
 
Other points 
1. Several repetitions should be avoided. For example, the information that 'BMI was evaluated 
in 380 patients' is given four times in the paper. 
Ok, repetitions have been deleted. 
 
2. Ref. 25 should be corrected. 
Ok, ref 25 has been edited. 
Figure Click here to access/download;Figure;Breccia et al_CCI-BMI&RUXO_AH_FIGURE
1_Revised.tiff
Figure Click here to access/download;Figure;Breccia et al_CCI-BMI&RUXO_AH_FIGURE
2_Revised.tiff
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Table 2. Ruxolitinib-induced anemia and thrombocytopenia according to Charlson Comorbidity Index (CCI) and Body Mass Index (BMI) 
at ruxolitinib start. Drug-induced anemia was defined as increasing in anemia grade with respect to baseline levels. Patients that were 
transfusion-dependent before the start of ruxolitinib therapy were not evaluable for drug-related anaemia.  
 
 
 
  ANEMIA THROMBOCYTOPENIA 
  CCI<3 CCI≥3 p BMI<21.9 BMI≥21.9 p CCI<3 CCI≥3 p BMI<21.9 BMI≥21.9 p 
Any time 
192/253 
(75.9%) 
37/50 
(74%) 
0.78 
52/69 172/224 
0.8 
168/326 
(51.5%) 
39/76 
(51.3%) 
0.97 
53/96 145/284 
0.48 
(75.4%) (76.8%) (55.2%) (51.1%) 
At 3 months 
170/253 34/50 
0.91 
49/69 151/224 
0.57 
94/326 23/76 
0.80 
31/96 79/284 
0.40 
(67.2%) (68.0%) (71.0%) (67.4%) (28.8%) (30.3%) (32.3%) (27.8%) 
At 6 months 
124/232 20/40 
0.69 
32/62 109/203 
0.77 
92/326 21/76 
0.92 
25/96 83/284 
0.55 
(53.45%) (50.0%) (51.6%) (53.7%) (28.2%) (27.6%) (26.0%) (29.2%) 
Table
 2 
 
 1 
Table 3. Ruxolitinib-induced anemia and thrombocytopenia according to Charlson Comorbidity Index (CCI) and Body Mass Index (BMI). 
Only patients with baseline haemoglobin ≥ 12 g/dl  (n. 132) and patients with baseline platelet count ≥ 150 x 109/l (n. 296) were considered 
evaluable.  
 
  
  
ANEMIA grade ≥2 THROMBOCYTOPENIA grade ≥2 
CCI<3 CCI≥3 p BMI<21.9 BMI≥21.9 p CCI<3 CCI≥3 p BMI<21.9 BMI≥21.9 p 
Any time 
40/116 
(34.5%) 
10/16 
(62.5%) 
0.03 
12/27 35/99 
0.39 
34/244 
(13.9%) 
9/52 
(17.3%) 
0.53 
12/67 30/217 
0.41 
(44.4%) (35.4%) (17.9%) (13.8%) 
At 3 months 
32/116  9/16 
0.02 
10/27 29/99 
0.44 
10/244 2/52 
0.92 
3/67 8/215 
0.78 
(27.6%) (56.3%) (37.0%) (29.3%) (4.1%) (3.8%) (4.48%) (3.7%) 
At 6 months 
24/108 4/12 
0.39 
6/24 21/92 
0.82 
13/217 3/45 
0.86 
5/60 11/195 
0.45 
(22.2%) (33.3%) (25.0%) (22.8%) (6.0%) (6.7%) (8.3%) (5.6%) 
 
 
Table
